Drugs that target wakefulness, molecules in cannabis and wearable devices that modulate brain activity could help people with ...

Japanese drugmaker Eisai (TYO: 4523) today announced that the in-house-discovered and developed orexin receptor antagonist Dayvigo (lemborexant) has been approved in China for the treatment of adults ...

DAYVIGO is a dual orexin receptor antagonist that inhibits orexin neurotransmission regulating sleep-wake rhythm by binding competitively to the two subtypes of orexin receptors (OX1R and OX2R).

(An active ingredient is what makes a drug work.) It belongs to a newer group of insomnia medications called dual orexin receptor antagonists (DORAs). It’s not currently available as a generic drug.

Medscape: This year, the European Medicines Agency issued a marketing authorization recommendation for the orexin receptor antagonist daridorexant (see box). The drug has been available on the ...

Idorsia has become the first drugmaker in the EU to claim approval for a drug for chronic insomnia in the dual orexin receptor antagonist class, ahead of rival drugs from Merck & Co and Eisai.

Yee: ALKS 2680 has a novel mechanism. It targets the orexin 2 receptors, and we know that the orexin pathway is very important in terms of maintaining wakefulness. So other treatment that we ...

First patent application was filed at the end of 2022 for orexin receptors agonists for treating or preventing neurological diseases and psychiatric disorders including narcolepsy. With this ...

We conducted a phase 2, randomized, placebo-controlled trial of TAK-994, an oral orexin receptor 2–selective ... Pitolisant, which targets histamine H3 receptors, and γ-hydroxybutyric acid ...

In 2014, suvorexant, an orexin receptor antagonist, was approved for treating insomnia, allowing for the physiological functions of orexin to be studied in humans. However, the role of the orexin ...